Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 28, 2021; 27(32): 5424-5437
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Table 3 Dose modification related to adverse events
| Group A (n = 41) | Group B (n = 30) | Group C (n = 63) | Group A vs Group B, P value | Group A vs Group C, P value | Group B vs Group C, P value | |
| Dose reduction to initial dose of sorafenib | 8/41 (19.5%) | 2/30 (6.7%) | 26/63 (41.3%) | 0.700 | 0.108 | 0.005 |
| Re-escalation to initial dose of sorafenib | 2/8 (25.0%) | 2/2 (100.0%) | 2/26 (7.7%) | NA | NA | NA |
- Citation: Ochi M, Kamoshida T, Araki M, Ikegami T. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. World J Gastroenterol 2021; 27(32): 5424-5437
- URL: https://www.wjgnet.com/1007-9327/full/v27/i32/5424.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i32.5424